文献速递消化道肿瘤与早癌消化内镜

循环肿瘤DNA分析用于局部食管癌放化疗后微小残留病灶检测

Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
PubMed 文献 · Gastroenterology · 2019-11-09

该研究对45例局部食管癌患者放化疗前后血浆游离DNA进行深度测序(CAPP-Seq),并设40例健康对照,发现放化疗后检出ctDNA与肿瘤进展、远处转移及疾病特异性生存期缩短显著相关,且可比影像学提前约2.8个月预警进展。

要点

  • 放化疗后ctDNA检出与肿瘤进展风险显著相关(HR 18.7,P<.0001)。
  • ctDNA检出比影像学进展平均提前2.8个月。
  • ctDNA联合代谢影像可提高进展预测率至100%。

核心结论

  • 局部食管癌放化疗后检出ctDNA与肿瘤进展、远处转移及疾病特异性生存期缩短显著相关。

研究设计与样本

  • 前瞻性队列分析,纳入45例局部食管癌患者(2010年5月至2015年10月治疗),其中23例后续接受食管切除术、22例未手术,另设40例健康对照。
  • 对血浆游离DNA、白细胞DNA及食管镜活检固定肿瘤样本进行CAPP-Seq深度测序,覆盖607个基因的802个区域。
  • 患者放化疗后6-8周接受影像学分析并随访5年,主要目的为确定放化疗后ctDNA检出是否与肿瘤进展风险相关。

主要发现

  • 治疗前肿瘤来源DNA占总游离DNA的中位比例为0.07%。
  • 放化疗后检出ctDNA与肿瘤进展相关(风险比18.7;P<.0001)。
  • 放化疗后检出ctDNA与远处转移形成相关(风险比32.1;P<.0001)。
  • 放化疗后检出ctDNA与较短疾病特异性生存期相关(风险比23.1;P<.0001)。
  • 肿瘤进展患者放化疗后血浆样本中新突变检出比例高于无进展患者(P=.03)。

临床怎么用

  • 放化疗后ctDNA检测可用于识别肿瘤进展高风险患者,辅助风险分层。
  • ctDNA动态监测可能较影像学更早提示进展,联合代谢影像可提高预测准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of additional therapy. METHODS: We performed deep sequencing (CAncer Personalized Profiling by deep Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy, and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy control individuals. We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6-8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) after chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy). RESULTS: The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA after chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P < .0001), formation of distant metastases (hazard ratio, 32.1; P < .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P < .0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P = .03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100% of patients with tumor progression, compared with 71% for only ctDNA detection and 57% for only metabolic imaging analysis (P < .001 for comparison of either technique to combined analysis). CONCLUSIONS: In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Azad TD, Chaudhuri AA, Fang P, et al. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology. 2019. PMID: 31711920. doi:10.1053/j.gastro.2019.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。